Ranbaxy Laboratories, Inc.

Abhijit Ray

Venkata Poornapragnacharyulu Palle

Sunanda Ghosh Dastidar

Sarala Balachandran

Sonali Rudra

Nidhi Gupta

Anita Mehta

Ashwani Kumar Verma

Biswajit Das

Ashok Rattan

Vinayak Vasantrao Khairnar

Sanjay Malhotra

Lalit Kumar Baregama

Sudershan Kumar Arora

Mohammad Salman

Viswajanani Jitendra Sattigeri

Manoj Kumar Khera

Sankaranarayanan Dharmarajan

Gagan Kukreja

Lalitha Vijaykrishnan

Mandadapu Raghuramaiah

Manohar Salla

Atul Kondaskar

Rajkumar Shirumalla

Saswati Chakladar

Sarika Ramnani

Nagarajan Muthukamal

Shirumalla Raj Kumar

Arora K Sudershan

Sreedhara Rao Voleti

Mandadapu Raghu Ramaiah

Sunanda Ghose Dastidar

Ritu Agarwal

The present invention relates to Compounds having the structure of Formula I: wherein n is an integer from 1 to 5; Ris optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; Ris alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NRR, &#x2014;NHC(&#x2550;Y)R, &#x2014;NHC(&#x2550;Y)NRR, &#x2014;NHC(&#x2550;O)OR, &#x2014;NHSOR, C(&#x2550;Y)NRR, C(&#x2550;O)OR[wherein Y is oxygen or sulphur], OR, &#x2014;O(C&#x2550;O)NRR, O-acyl, S(O)R, &#x2014;SON(R), cyano, amidino or guanidino [wherein Ris alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; Ris hydrogen or R; Ris Ror &#x2014;SON(R)and Ris hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; Ris hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR, &#x2014;OC(&#x2550;O)NRR, O-acyl, NH, NRR, &#x2014;NHC(&#x2550;Y)R, &#x2014;NHC(&#x2550;Y)NRR, &#x2014;NHC(&#x2550;O)OR, &#x2014;NHSOR, and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds. 

5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided. 

Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV Formula (XIV). 

Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.

Inhibitors of phosphodiesterase type-IV

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

Monosaccharide derivatives

The present invention relates to isoxazoline derivatives of structure Ia, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type IV inhibitors. 

Substituted indazoles as inhibitors of phosphodiesterase type-IV

The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory, and autoimmune diseases. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as 5-lipoxygenase inhibitors are also provided.

5-lipoxygenase inhibitors

The present invention relates to certain substituted phenyl piperazinyl oxazolidinones, for example, to those having the structure of Formula Iwith the variables as defined within, and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such asspp. andspp. species, and acid fast organisms such asandspp.

Oxazolidinone piperazinyl derivatives as potential antimicrobials

The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as and Mycobacterium spp.

Oxazolidinone derivatives as antimicrobials

Growing community of inventors

New Delhi, India

Abhijit Ray